|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3630200A
(en)
|
1969-06-09 |
1971-12-28 |
Alza Corp |
Ocular insert
|
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US3847770A
(en)
|
1972-04-10 |
1974-11-12 |
Continental Can Co |
Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
|
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US3936354A
(en)
|
1974-04-29 |
1976-02-03 |
Lapointe Jean Rock |
Anti-tumour product of bacterial origin
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
GB8322007D0
(en)
|
1983-08-16 |
1983-09-21 |
Wellcome Found |
Pharmaceutical delivery system
|
|
US4769027A
(en)
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
DK1621554T4
(da)
|
1992-08-21 |
2012-12-17 |
Univ Bruxelles |
Immunoglobuliner blottet for lette kæder
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US6190657B1
(en)
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
CN1253551C
(zh)
|
1997-09-10 |
2006-04-26 |
维昂药品公司 |
减毒的遗传修饰肿瘤靶向细菌
|
|
JP2001010973A
(ja)
|
1999-06-29 |
2001-01-16 |
Dnavec Research Inc |
がんワクチン
|
|
US6962696B1
(en)
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
|
CA2386806A1
(en)
|
1999-10-04 |
2001-04-12 |
Vion Pharmaceuticals, Inc. |
Non-invasive tumor imaging by tumor-targeted bacteria
|
|
AU2001227889A1
(en)
|
2000-01-14 |
2001-07-24 |
The United States of America, represented by The Secretary, Department of Health & Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
WO2003045153A1
(en)
|
2001-11-21 |
2003-06-05 |
The Johns Hopkins University |
Combination bacteriolytic therapy for the treatment of tumors
|
|
WO2003065787A2
(en)
|
2002-02-06 |
2003-08-14 |
Johns Hopkins University School Of Medicine |
Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
|
|
US20070298012A1
(en)
|
2003-12-16 |
2007-12-27 |
Ivan King |
Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
|
|
US8501198B2
(en)
|
2004-06-07 |
2013-08-06 |
Qu Biologics Inc. |
Tissue targeted antigenic activation of the immune response to treat cancers
|
|
WO2006004992A1
(en)
|
2004-06-29 |
2006-01-12 |
Anticancer, Inc. |
Cancer selective auxotrophs
|
|
US20090123426A1
(en)
|
2004-12-17 |
2009-05-14 |
Chiang Li |
Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
|
|
US8426375B2
(en)
|
2005-10-12 |
2013-04-23 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
|
JP4842749B2
(ja)
*
|
2006-04-19 |
2011-12-21 |
花王株式会社 |
組換え微生物
|
|
CN1974759B
(zh)
|
2006-07-26 |
2010-06-09 |
吉林大学 |
运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用
|
|
US8241844B2
(en)
|
2008-10-03 |
2012-08-14 |
Ralph Clark, legal representative |
Methods and compositions for modulating an immune response with immunogenic oligonucleotides
|
|
US20120009153A1
(en)
|
2009-08-13 |
2012-01-12 |
Hongnian Guo |
Compositions for bacterial mediated gene silencing and methods of using the same
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
EP2620159A1
(en)
|
2012-01-24 |
2013-07-31 |
Institut Pasteur |
Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
|
|
CN103374538B
(zh)
|
2012-04-27 |
2017-12-01 |
山东新创生物科技有限公司 |
包含戈氏梭菌(Clostridiumghonii)的衍生细菌菌株的组合物及其使用方法
|
|
ES2391108B1
(es)
|
2012-07-26 |
2013-10-07 |
Universitat Autonoma De Barcelona |
Uso de mycobacterium brumae para el tratamiento del cáncer de vejiga
|
|
US9539290B2
(en)
|
2012-12-24 |
2017-01-10 |
Anticancer Inc. |
Individualized bacterial treatment of pancreatic cancer
|
|
DK2986311T3
(en)
|
2013-04-18 |
2019-02-25 |
Tilt Biotherapeutics Oy |
IMPROVED ADOPTIVE CELL THERAPY
|
|
WO2015002969A1
(en)
|
2013-07-03 |
2015-01-08 |
City Of Hope |
Anticancer combinations
|
|
US10987432B2
(en)
|
2013-09-05 |
2021-04-27 |
The University Of Hong Kong |
Therapeutic delivery and expression system, methods and uses thereof
|
|
HUE035875T2
(hu)
|
2013-10-25 |
2018-06-28 |
Psioxus Therapeutics Ltd |
Heterológ géneket tartalmazó onkolitikus adenovírusok
|
|
WO2015153639A1
(en)
|
2014-03-31 |
2015-10-08 |
The Johns Hopkins University |
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
|
|
WO2016025582A2
(en)
|
2014-08-12 |
2016-02-18 |
Forbes Neil S |
Targeting epigenetic regulators using a bacterial delivery system
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
US9688967B2
(en)
|
2014-12-05 |
2017-06-27 |
Synlogic, Inc. |
Bacteria engineered to treat diseases associated with hyperammonemia
|
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
|
ES2881384T3
(es)
|
2015-05-13 |
2021-11-29 |
Synlogic Operating Co Inc |
Bacterias manipuladas para reducir la hiperfenilalaninemia
|
|
WO2016210373A2
(en)
*
|
2015-06-24 |
2016-12-29 |
Synlogic, Inc. |
Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
|
|
US11273184B2
(en)
|
2015-08-31 |
2022-03-15 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat disorders in which oxalate is detrimental
|
|
WO2017043815A1
(en)
|
2015-09-08 |
2017-03-16 |
Sillajen, Inc. |
Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
CN110402145A
(zh)
|
2016-10-26 |
2019-11-01 |
莫得纳特斯公司 |
用于增强免疫应答的信使核糖核酸及其使用方法
|
|
BR112019013863A2
(pt)
*
|
2017-01-06 |
2020-03-03 |
Synlogic Operating Company, Inc. |
Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais
|
|
SG11201906552WA
(en)
|
2017-01-25 |
2019-08-27 |
Tessa Therapeutics Pte Ltd |
TGF-ß DECOY RECEPTOR
|
|
WO2018191619A1
(en)
*
|
2017-04-13 |
2018-10-18 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
EP4599893A3
(en)
|
2017-04-14 |
2025-11-05 |
CG Oncology, Inc. |
Cg0070 for treating bcg resistant bladder carcinoma in situ
|
|
CN108795832B
(zh)
*
|
2017-04-26 |
2021-05-14 |
江苏恒瑞医药股份有限公司 |
一种内源l-门冬酰胺酶ii基因敲除的宿主菌、其制备方法及其应用
|
|
EP3652318A1
(en)
|
2017-07-11 |
2020-05-20 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
WO2019035901A1
(en)
*
|
2017-08-15 |
2019-02-21 |
University Of Miami |
COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION
|
|
WO2019183117A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Multivir Inc. |
Methods and compositions comprising genetically engineered vaccines for the treatment and prevention of cancer
|
|
JP7340591B2
(ja)
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
WO2020172462A1
(en)
|
2019-02-22 |
2020-08-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
|
|
US11717542B2
(en)
|
2019-02-22 |
2023-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Using tumor-navigating Salmonella to modulate tumor metabolism
|
|
JP2023501539A
(ja)
*
|
2019-11-12 |
2023-01-18 |
アクティム・セラピューティクス・インコーポレイテッド |
免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
|